Merck & Co., Inc. Stock Forecast, Price & News

$75.45
-0.82 (-1.08 %)
(As of 06/14/2021 04:39 PM ET)
Add
Compare
Today's Range
$74.88
$75.80
50-Day Range
$72.40
$79.87
52-Week Range
$15.32
$87.80
Volume7.82 million shs
Average Volume11.90 million shs
Market Capitalization$191.04 billion
P/E Ratio27.34
Dividend Yield3.41%
Beta0.4
30 days | 90 days | 365 days | Advanced Chart
Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.


Merck & Co., Inc. logo

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases). Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

21st out of 2,100 stocks

Pharmaceutical Preparations Industry

7th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc.
or view top-rated stocks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Merck & Co., Inc.
.

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Thursday, April, 29th. The company reported $1.40 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.63 by $0.23. The business had revenue of $12.08 billion for the quarter, compared to analysts' expectations of $12.71 billion. Merck & Co., Inc. had a net margin of 14.64% and a trailing twelve-month return on equity of 54.15%. The firm's quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.50 earnings per share.
View Merck & Co., Inc.'s earnings history
.

How has Merck & Co., Inc.'s stock been impacted by Coronavirus (COVID-19)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRK stock has decreased by 4.8% and is now trading at $75.46.
View which stocks have been most impacted by COVID-19
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a dividend on Tuesday, June 1st. Shareholders of record on Friday, June 4th will be given a dividend of $0.65 per share on Wednesday, June 2nd. This represents a dividend yield of 3.42%. The ex-dividend date is Thursday, June 3rd.
View Merck & Co., Inc.'s dividend history
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.41%. Merck & Co., Inc. does not yet have a strong track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.35% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided earnings per share (EPS) guidance of 6.480-6.680 for the period, compared to the Thomson Reuters consensus estimate of $6.570. The company issued revenue guidance of $51.80 billion-$53.80 billion, compared to the consensus revenue estimate of $52.51 billion.

What price target have analysts set for MRK?

12 equities research analysts have issued 12 month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $88.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $96.11 in the next year. This suggests a possible upside of 27.4% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Mr. Kenneth C. Frazier, CEO & Chairman (Age 66, Pay $4.3M)
  • Mr. Robert M. Davis, Pres (Age 54, Pay $2.29M)
  • Ms. Jennifer L. Zachary, Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $1.79M)
  • Mr. Sanat Chattopadhyay, Exec. VP & Pres of Merck Manufacturing Division (Age 61, Pay $1.56M)
  • Ms. Caroline Litchfield, Exec. VP & CFO
  • Mr. David Michael Williams, Chief Information & Digital Officer
  • Mr. Peter Dannenbaum CFA, VP of Investor Relations
  • Michael W. Fleming, Sr. VP and Chief Ethics & Compliance Officer (Age 62)
  • Ms. Jennifer Mauer, VP of Global Communications
  • Mr. Steven C. Mizell, Exec. VP & Chief HR Officer (Age 61)

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.66%), Geode Capital Management LLC (1.69%), Franklin Resources Inc. (1.40%), Capital International Investors (1.31%), Northern Trust Corp (1.27%) and Bank of New York Mellon Corp (1.21%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Richard R Deluca, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Berkshire Hathaway Inc, Nuveen Asset Management LLC, BlackRock Inc., Brandywine Global Investment Management LLC, TD Asset Management Inc., Bank of Nova Scotia, Capital International Investors, and Schafer Cullen Capital Management Inc. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc.
or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Arrowstreet Capital Limited Partnership, Massachusetts Financial Services Co. MA, Man Group plc, Cullen Capital Management LLC, Nordea Investment Management AB, Factorial Partners LLC, and Orbimed Advisors LLC.
View insider buying and selling activity for Merck & Co., Inc.
or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $75.46.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $191.07 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $5.94 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 74,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.